An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials
- PMID: 17210187
- DOI: 10.1016/j.jviromet.2006.11.024
An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials
Abstract
We describe a method for the generation of clinical grade, live-attenuated vaccines in Vero cells entirely from cDNA plasmids. The entire electroporation procedure can be completed in less than 15 minutes and this is a significant improvement over previous lipid or electroporation based transfection techniques that also involve a heat-shock step. Importantly, the virus preparations can be generated with a minimal use of animal product derived materials, an important consideration for a vaccine candidate that is to be tested in humans. Since it is likely that all live-attenuated parainfluenza virus and pneumovirus vaccines in the future will be generated using reverse genetics, this simplified method provides guidance on how this can be achieved.
Similar articles
-
Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.Virol J. 2007 Jul 2;4:67. doi: 10.1186/1743-422X-4-67. Virol J. 2007. PMID: 17605811 Free PMC article.
-
Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.J Virol. 2000 Jul;74(14):6448-58. doi: 10.1128/jvi.74.14.6448-6458.2000. J Virol. 2000. PMID: 10864657 Free PMC article.
-
An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development.J Virol Methods. 2006 Jul;135(1):91-101. doi: 10.1016/j.jviromet.2006.02.006. Epub 2006 Mar 29. J Virol Methods. 2006. PMID: 16569439
-
Prospects for a parainfluenza virus vaccine.Pediatr Pulmonol Suppl. 1997;16:280-1. doi: 10.1002/ppul.19502308145. Pediatr Pulmonol Suppl. 1997. PMID: 9443313 Review. No abstract available.
-
Current status of vaccines for parainfluenza virus infections.Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S123-5. doi: 10.1097/INF.0b013e318168b76f. Pediatr Infect Dis J. 2008. PMID: 18820572 Review.
Cited by
-
Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.Vaccine. 2012 Jun 6;30(26):3975-81. doi: 10.1016/j.vaccine.2011.12.022. Epub 2011 Dec 14. Vaccine. 2012. PMID: 22178099 Free PMC article.
-
Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.J Virol Methods. 2010 Mar;164(1-2):43-50. doi: 10.1016/j.jviromet.2009.11.023. Epub 2009 Nov 24. J Virol Methods. 2010. PMID: 19941901 Free PMC article.
-
Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.Virol J. 2007 Jul 2;4:67. doi: 10.1186/1743-422X-4-67. Virol J. 2007. PMID: 17605811 Free PMC article.
-
Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease.Curr Top Microbiol Immunol. 2013;372:3-38. doi: 10.1007/978-3-642-38919-1_1. Curr Top Microbiol Immunol. 2013. PMID: 24362682 Free PMC article.
-
Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.Virus Res. 2011 Dec;162(1-2):80-99. doi: 10.1016/j.virusres.2011.09.020. Epub 2011 Sep 22. Virus Res. 2011. PMID: 21963675 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
